Key result
Apolipoprotein polymorphisms influence the phenotype and cardiovascular disease risk in patients with familial hypercholesterolemia.
Why the study?
How do apolipoprotein polymorphisms influence the phenotype and cardiovascular risk in patients with familial hypercholesterolemia?
How do apolipoprotein polymorphisms influence the phenotype and cardiovascular risk in patients with familial hypercholesterolemia?
Apolipoprotein polymorphisms act as genetic modifiers that influence the clinical phenotype and cardiovascular risk in patients with familial hypercholesterolemia.
No takes yet. Share an insight, caveat, or question.
Apolipoprotein polymorphisms may modify FH phenotype and CVD risk; hypothesis-generating, requires prospective validation before clinical use.
George V Z Dedoussis (2007) conducted a review in Familial hypercholesterolemia. Apolipoprotein polymorphisms was evaluated. Apolipoprotein polymorphisms influence the phenotype and cardiovascular disease risk in patients with familial hypercholesterolemia.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: